EdenRoc Sciences Board
Edward Schulak
Chairman
Mr. Schulak , Founder and Chairman of EdenRoc Sciences, is an architect, philanthropist, and life sciences investor.
He has served on numerous charitable, academic, and business boards, including the Sanford Burnham Prebys Medical Discovery Institute, the Advisory Board of the New York University Center for Urban Science and currently on the Boards of The University of Michigan Health System Advisory Group (Hospital, Research Center and Medical School), the Harvard Medical School Dean’s Discovery Council, Novim and the Dean’s Council for the University of California Baskin School of Engineering.
Mr. Schulak graduated from the Rhode Island School of Design with degrees in both Fine Arts and Architecture.
David Sinclair, Ph.D.
Vice Chairman
Dr. Sinclair, EdenRoc Vice Chairman, is a tenured professor in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for the Biology of Aging Research.
He is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious and rare diseases.
Dr. Sinclair obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney in 1995. He worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability. In 1999, he was recruited to Harvard Medical School where his laboratory’s research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer.
Carlos Bustamante, Ph.D.
EdenRoc Director
Dr. Bustamante, EdenRoc Director, is an internationally recognized leader in the application of data science and genomics technology to problems in medicine, agriculture, and biology. He is Founding Director of the Stanford Center for Computational, Evolutionary, and Human Genomics (CEHG) and Inaugural Chair of the Department of Biomedical Data Science.
Dr. Bustamante received his Ph.D. in Biology and MS in Statistics from Harvard University (2001), was on the faculty at Cornell University (2002-9) and was named a MacArthur Fellow in 2010. He is currently Professor of Biomedical Data Science, Genetics, and (by courtesy) Biology at Stanford University. Dr. Bustamante has a passion for building new academic units, non-profits, and companies to solve pressing scientific challenges.
Edward Schulak
Chairman
Mr. Schulak , Founder and Chairman of EdenRoc Sciences, is an architect, philanthropist, and life sciences investor.
He has served on numerous charitable, academic, and business boards, including the Sanford Burnham Prebys Medical Discovery Institute, the Advisory Board of the New York University Center for Urban Science and currently on the Boards of The University of Michigan Health System Advisory Group (Hospital, Research Center and Medical School), the Harvard Medical School Dean’s Discovery Council, Novim and the Dean’s Council for the University of California Baskin School of Engineering.
Mr. Schulak graduated from the Rhode Island School of Design with degrees in both Fine Arts and Architecture.
David Sinclair, Ph.D.
Vice Chairman
Dr. Sinclair, EdenRoc Vice Chairman, is a tenured professor in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for the Biology of Aging Research.
He is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious and rare diseases.
Dr. Sinclair obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney in 1995. He worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability. In 1999, he was recruited to Harvard Medical School where his laboratory’s research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer.
Board (horizontal options)
Mr. Schulak , Founder and Chairman of EdenRoc Sciences, is an architect, philanthropist, and life sciences investor.
He has served on numerous charitable, academic, and business boards, including the Sanford Burnham Prebys Medical Discovery Institute, the Advisory Board of the New York University Center for Urban Science and currently on the Boards of The University of Michigan Health System Advisory Group (Hospital, Research Center and Medical School), the Harvard Medical School Dean’s Discovery Council, Novim and the Dean’s Council for the University of California Baskin School of Engineering.
Mr. Schulak graduated from the Rhode Island School of Design with degrees in both Fine Arts and Architecture.
Edward Schulak
Chairman
Dr. Sinclair, EdenRoc Vice Chairman, is a tenured professor in the Department of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for the Biology of Aging Research.
He is regarded as one of the world’s leading researchers on aging and age-associated diseases, with key contributions to understanding why we age and how to slow and even reverse the process. He has co-founded multiple biotechnology and genomics companies working on aging, neurological, metabolic, infectious and rare diseases.
Dr. Sinclair obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney in 1995. He worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability. In 1999, he was recruited to Harvard Medical School where his laboratory’s research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer.
David Sinclair, Ph.D.
Vice Chairman
